Featured Research

from universities, journals, and other organizations

The good, the bad and the ugly: the many roles of c-JUN in cancer

Date:
June 28, 2011
Source:
Veterinärmedizinische Universität Wien
Summary:
The process of cell division is tightly regulated, as mistakes may lead to cancer. The so-called c-JUN protein has been fingered as causing tumors in both skin and liver. It has long been known to have a direct role in reducing the expression of a gene (p53) that leads to the death of abnormal cells and to activate transcription of a further gene (CyclinD1) that directly promotes cell division. Researchers recently showed that c-JUN has a further activity by which it drives unwanted cell division: it binds the promoter of another gene involved in cell-cycle regulation, thereby preventing it from being silenced. The researchers have now uncovered a further surprising detail with the discovery that c-JUN's new function also prevents silencing of p16, an important anti-tumor factor.

The process of cell division is tightly regulated, as mistakes may lead to cancer. The so-called c-JUN protein has been fingered as causing tumours in both skin and liver. It has long been known to have a direct role in reducing the expression of a gene (p53) that leads to the death of abnormal cells and to activate transcription of a further gene (CyclinD1) that directly promotes cell division. The group of Veronika Sexl at the University of Veterinary Medicine, Vienna recently showed that c-JUN has a further activity by which it drives unwanted cell division: it binds the promoter of another gene involved in cell-cycle regulation, thereby preventing it from being silenced. The researchers have now uncovered a further surprising detail with the discovery that c-JUN's new function also prevents silencing of p16, an important anti-tumour factor. The finding adds a further layer of complexity to the regulation of cell division.

The results have recently been published in the open access journal Oncotarget.

The c-JUN protein was initially described in the late 1980s as the mammalian equivalent of a protein responsible for causing cancer in birds. Intense research in a number of labs has subsequently led to a basic understanding of how the protein works. c-JUN is a transcription factor that modifies (phosphorylates) key regulatory proteins in the cell, thereby activating or deactivating them and leading to unregulated cell division and hence cancer. It has also become clear that c-JUN acts not on its own but in conjunction with an array of further proteins that modulate its function.

Karoline Kollmann in the group of Veronika Sexl, now at the University of Veterinary Medicine, Vienna, recently discovered an additional activity of c-JUN. Together with her collaboration partners at the Medical University of Vienna and in Madrid, she showed that c-JUN can bind to the promoter of a kinase gene, known as Cdk6, thereby preventing the gene from being inactivated (by means of methylation). The result is increased activity of Cdk6, which further stimulates cell division. c-JUN only activates transcription of Cdk6 in cancer cells, where it makes the disease progress even faster. Kollmann's work was published in April in the journal Blood (2011, Vol. 117, pp. 4065-4075).

The surprising aspect of the discovery is that the "new" function of c-JUN is independent of the protein's normal activity. Kollmann has now added a further twist to the tail with the discovery that c-JUN protects not only the Cdk6 gene -- thereby accelerating tumour formation -- but also the p16 gene. p16 is a known tumour suppressor gene and its mutation or inactivation is associated with an increased risk of contracting a variety of forms of cancer. By protecting its promoter from inactivation, c-JUN seems to be helping the cells to fight the cancer.

Does this mean that the main villain of the piece is not actually as bad as we thought? Kollmann's response is fairly guarded. "I think it means that the functions of all these proteins are far more complex than we know. They all work together with many other proteins and the overall effect probably depends on a large number of factors. We have a lot more to learn before we can understand what proteins to inhibit to treat the disease."


Story Source:

The above story is based on materials provided by Veterinärmedizinische Universität Wien. Note: Materials may be edited for content and length.


Journal Reference:

  1. Karoline Kollmann, Gerwin Heller, Veronika Sexl. c-JUN prevents methylation of p16INK4a (and Cdk6): the villain turned bodyguard. Oncotarget, May 28, 2011 [link]

Cite This Page:

Veterinärmedizinische Universität Wien. "The good, the bad and the ugly: the many roles of c-JUN in cancer." ScienceDaily. ScienceDaily, 28 June 2011. <www.sciencedaily.com/releases/2011/06/110628094823.htm>.
Veterinärmedizinische Universität Wien. (2011, June 28). The good, the bad and the ugly: the many roles of c-JUN in cancer. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2011/06/110628094823.htm
Veterinärmedizinische Universität Wien. "The good, the bad and the ugly: the many roles of c-JUN in cancer." ScienceDaily. www.sciencedaily.com/releases/2011/06/110628094823.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) — The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) — Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) — America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) — A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:  

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile iPhone Android Web
          Follow Facebook Twitter Google+
          Subscribe RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins